New decision aid aims to boost liver cancer screening in veterans

NCT ID NCT06061328

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new decision aid tool (OASIS) that helps VA hospitals choose the best strategies to improve screening for liver cancer in patients with cirrhosis. Over 8,000 veterans and clinicians at multiple VA medical centers will participate. The goal is to see if the tool leads to more patients getting recommended abdominal imaging every six months, ultimately catching cancers earlier.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OASIS decision aid training (a tool to help select implementation strategies)
What this could lead to: If successful, this could provide a simple, data-driven way for hospitals to adopt proven screening methods for liver cancer, improving early detection and patient outcomes.
What could go wrong: This is a large implementation study, not a test of a new drug or treatment. The tool may not improve screening rates as hoped, and results may not apply outside the VA system.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis hepatocellular carcinoma Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CIRRHOSIS HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA

Pittsburgh, Pennsylvania, 15240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.